Skip to main content
Journal cover image

Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer.

Publication ,  Journal Article
Fernando, NH; Hurwitz, HI
Published in: Semin Oncol
June 2003

Angiogenesis is essential for tumor growth and metastasis and is a promising target in the search for new anti-neoplastic agents. Angiogenesis is a tightly regulated process dependent on the complex interplay between inhibitory and stimulatory angiogenic factors. Vascular endothelial growth factor is one of the best characterized of the pro-angiogenic growth factors, and multiple strategies have been developed to inhibit this pathway. Bevacizumab, a monoclonal antibody developed against vascular endothelial growth factor, has shown initial preclinical and clinical activity. This review will outline the conceptual basis of anti-angiogenic therapy, discuss the critical role of vascular endothelial growth factor, and summarize the available data on the use of bevacizumab in colorectal cancer.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Semin Oncol

DOI

ISSN

0093-7754

Publication Date

June 2003

Volume

30

Issue

3 Suppl 6

Start / End Page

39 / 50

Location

United States

Related Subject Headings

  • Vascular Endothelial Growth Factors
  • Vascular Endothelial Growth Factor A
  • Oncology & Carcinogenesis
  • Lymphokines
  • Intercellular Signaling Peptides and Proteins
  • Humans
  • Endothelial Growth Factors
  • Drug Screening Assays, Antitumor
  • Colorectal Neoplasms
  • Clinical Trials as Topic
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Fernando, N. H., & Hurwitz, H. I. (2003). Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol, 30(3 Suppl 6), 39–50. https://doi.org/10.1016/s0093-7754(03)00124-6
Fernando, Nishan H., and Herbert I. Hurwitz. “Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer.Semin Oncol 30, no. 3 Suppl 6 (June 2003): 39–50. https://doi.org/10.1016/s0093-7754(03)00124-6.
Fernando NH, Hurwitz HI. Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol. 2003 Jun;30(3 Suppl 6):39–50.
Fernando, Nishan H., and Herbert I. Hurwitz. “Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer.Semin Oncol, vol. 30, no. 3 Suppl 6, June 2003, pp. 39–50. Pubmed, doi:10.1016/s0093-7754(03)00124-6.
Fernando NH, Hurwitz HI. Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol. 2003 Jun;30(3 Suppl 6):39–50.
Journal cover image

Published In

Semin Oncol

DOI

ISSN

0093-7754

Publication Date

June 2003

Volume

30

Issue

3 Suppl 6

Start / End Page

39 / 50

Location

United States

Related Subject Headings

  • Vascular Endothelial Growth Factors
  • Vascular Endothelial Growth Factor A
  • Oncology & Carcinogenesis
  • Lymphokines
  • Intercellular Signaling Peptides and Proteins
  • Humans
  • Endothelial Growth Factors
  • Drug Screening Assays, Antitumor
  • Colorectal Neoplasms
  • Clinical Trials as Topic